Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Prospective, Observational Post-Authorization Safety Study to Evaluate the Safety Profile of Budesonide/Glycopyrrolate/Formoterol MDI in Chinese Patients With COPD in Routine Clinical Practice

NCT04536402 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04536402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04536402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Prospective, Observational Post-Authorization Safety Study to Evaluate the Safety Profile of Budesonide/Glycopyrrolate/Formoterol MDI in Chinese Patients With COPD in Routine Clinical Practice
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
March 16, 2021
Completion date
November 8, 2023
Enrollment
3,520 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease